抗寄生虫薬市場：薬剤タイプ、剤形、適応症、流通チャネル、エンドユーザー別-2025-2030年世界予測

抗寄生虫薬市場は、2023年に204億米ドルと評価され、2024年には211億2,000万米ドルに達すると予測され、CAGR 4.59%で成長し、2030年には279億4,000万米ドルに達すると予測されています。

抗寄生虫薬は、ヒトや動物の寄生虫感染症の管理に不可欠であり、世界ヘルスにおいて重要な役割を果たしています。これらの治療薬は、広域スペクトル剤から蠕虫、原虫、外部寄生虫などの特定の寄生虫を標的とするものまで多岐にわたり、治療と予防ヘルスケアの両面で極めて重要な役割を担っています。これらの薬剤の必要性は、特に熱帯地域でマラリア、リーシュマニア症、住血吸虫症などの病気が多発していることからも明らかです。最終用途は、病院、診療所、製薬企業、農業部門など多岐にわたる。市場開拓の原動力は、意識の向上、医療費の増加、医薬品開発技術の進歩です。植物由来の抗寄生虫薬や薬剤耐性に対処する次世代製剤など、新規治療薬に対する需要から注目すべき機会が生まれます。また、家畜生産とペット飼育の活発化により、動物用抗寄生虫薬セグメントの重要性が急増していることも、有利な見通しをもたらしています。

しかし、この分野は、厳しい規制環境、特定の抗寄生虫薬の副作用の可能性、遠隔地での薬剤流通の困難さなどの制約に直面しています。寄生虫の薬剤耐性化が急速に進んでいることも大きな課題であり、継続的な技術革新と研究が必要です。先駆的な研究分野としては、抗寄生虫薬としての合成カンナビノイドの開発、伝統的な薬用植物の探索、有効性を高め耐性リスクを低減するためのナノ粒子ベースの薬剤キャリアのようなデリバリーシステムの強化などが挙げられます。これらのハードルに対処するためには、製薬会社、研究機関、国際保健機関の協力が不可欠です。

要するに、抗寄生虫薬市場は、力強い成長の可能性と多面的な課題の両方を特徴とするダイナミックな市場なのです。現在のビジネスチャンスを活かそうとする利害関係者は、製剤の改良、診断ツールの改善、市場浸透のためのパートナーシップの活用に注力すべきです。この分野が発展していく中で、世界ヘルスと市場の持続可能性に最大限の影響を与えるためには、技術革新とアクセシビリティのバランスをとることが極めて重要であることに変わりはないです。

市場力学：急速に進化する抗寄生虫薬市場の主要市場インサイトを公開

抗寄生虫薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の寄生虫感染症の発生率と認知度の高まり
  • 寄生虫感染管理に対する政府の好意的な取り組み
  • 研究開発への投資の増加
• 市場抑制要因
  • 医薬品開発に莫大な資金が必要
• 市場機会
  • 複数の規制当局による抗寄生虫薬の承認急増
  • メーカーによる新規抗寄生虫薬のイントロダクション
• 市場の課題
  • 医薬品に関連する副作用とリスク

ポーターのファイブフォース：抗寄生虫薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：抗寄生虫薬市場における外部からの影響の把握

外部マクロ環境要因は、抗寄生虫薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析抗寄生虫薬市場における競合情勢の把握

抗寄生虫薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス抗寄生虫薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、抗寄生虫薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨抗寄生虫薬市場における成功への道筋を描く

抗寄生虫薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で寄生虫感染の発生率と認知度が増加
    • 寄生虫感染管理に対する政府の好ましい取り組み
    • 研究開発活動への投資の増加
  • 抑制要因
    • 医薬品開発には巨額の資金が必要
  • 機会
    • 複数の規制当局による抗寄生虫薬の承認が急増
    • メーカーによる斬新な抗寄生虫薬のイントロダクション
  • 課題
    • 薬剤に関連する副作用とリスク
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 抗寄生虫薬市場薬の種類別

• 駆虫薬
• 抗原虫
• 外部寄生虫駆除剤
• 寄生虫駆除剤

第7章 抗寄生虫薬市場：形態別

• 注射
• 経口錠剤/カプセル
• 外用クリーム

第8章 抗寄生虫薬市場適応症別

• ノミ
• 腸内寄生虫
• シラミ
• マラリア
• 疥癬
• ダニ

第9章 抗寄生虫薬市場：流通チャネル別

• オフライン
• オンライン

第10章 抗寄生虫薬市場：エンドユーザー別

• 在宅介護施設
• 病院・クリニック
• 獣医クリニック

第11章 南北アメリカの抗寄生虫薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の抗寄生虫薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの抗寄生虫薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Adva Care Pharma
• Algen Healthcare Ltd.
• Amneal Pharmaceuticals LLC
• Bayer AG
• Ben Pharmaceuticals
• Centurion Laboratories Private Limited
• Cipla Ltd.
• Consern Pharma Limited
• Dr.Reddys Laboratories Inc.
• F. Hoffmann-La Roche AG
• Fredun Group
• Garcia Life Sciences
• Glaxosmithkline PLC
• Healthy Life Pharma Private Limited
• Ipca Laboratories
• Jackson Laboratories Pvt Ltd.
• Mankind Pharma
• Merck KgaA
• Novartis AG
• Sanofi
• Soigner Pharma by Arlak Biotech
• Sriwalls Health Care
• Taj Life Sciences Pvt. Ltd.
• Weefsel Pharma
• Zydus Group

LIST OF FIGURES

• FIGURE 1. ANTIPARASITIC DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. ANTIPARASITIC DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. ANTIPARASITIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. ANTIPARASITIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTIPARASITIC DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTIPARASITIC DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ANTIPROTOZOALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ENDOPARACITICIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ORAL TABLETS/CAPSULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY TOPICAL CREAMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FLEAS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY INTESTINAL PARASITES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LICE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MALARIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SCABIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY TICKS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. CANADA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CANADA ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 48. CANADA ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. CANADA ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. CANADA ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES ANTIPARASITIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. CHINA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 74. CHINA ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 75. CHINA ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. CHINA ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. CHINA ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. INDIA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 79. INDIA ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 80. INDIA ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. INDIA ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. INDIA ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. ITALY ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 165. ITALY ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 166. ITALY ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 167. ITALY ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 168. ITALY ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. POLAND ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 185. POLAND ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 186. POLAND ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 187. POLAND ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. POLAND ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. QATAR ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 190. QATAR ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 191. QATAR ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. QATAR ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 193. QATAR ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM ANTIPARASITIC DRUGS MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM ANTIPARASITIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM ANTIPARASITIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM ANTIPARASITIC DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 239. ANTIPARASITIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 240. ANTIPARASITIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Antiparasitic Drugs Market was valued at USD 20.40 billion in 2023, expected to reach USD 21.12 billion in 2024, and is projected to grow at a CAGR of 4.59%, to USD 27.94 billion by 2030.

Antiparasitic drugs, essential in managing parasitic infections in humans and animals, serve a critical role in global health. These medications range from broad-spectrum agents to those targeting specific parasites like helminths, protozoa, or ectoparasites, and are pivotal in both treatment and preventive healthcare. The necessity of these drugs is underscored by the high prevalence of diseases like malaria, leishmaniasis, and schistosomiasis, particularly in tropical regions. Applications span human and veterinary medicine, with end-use scope encompassing hospitals, clinics, pharmaceutical enterprises, and agrarian sectors. Market growth is driven by increased awareness, rising healthcare expenditure, and advances in drug development technologies. Notable opportunities arise from the demand for novel therapeutics, including plant-based antiparasitics and next-generation formulations addressing drug resistance. The burgeoning importance of the veterinary antiparasitic segment, precipitated by intensified livestock production and pet ownership, also presents lucrative prospects.

However, the field faces constraints such as stringent regulatory environments, potential side effects of certain antiparasitic agents, and difficulties in drug distribution in remote areas. The rapid pace of drug resistance among parasites poses a significant challenge, necessitating continuous innovation and research. Pioneering areas for research include the development of synthetic cannabinoids as antiparasitics, exploration of traditional medicinal plants, and the enhancement of delivery systems like nanoparticle-based drug carriers to increase efficacy and reduce resistance risks. Collaborative efforts among pharmaceutical companies, research institutions, and international health organizations are imperative to address these hurdles.

In essence, the antiparasitic drugs market is dynamic, characterized by both robust growth potential and multifaceted challenges. Stakeholders seeking to capitalize on current opportunities should focus on advancing drug formulations, improving diagnostic tools, and leveraging partnerships for enhanced market penetration. As the field evolves, it remains crucial to balance innovation with accessibility to maximize impact on global health and market sustainability.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antiparasitic Drugs Market

The Antiparasitic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing incidence and awareness of parasite infection across the globe
  • Favorable government initiatives for parasite infection management
  • Increasing investment in research and development activities
• Market Restraints
  • Requirement of huge capital for drug development
• Market Opportunities
  • Surge in approvals for antiparasitic drugs from several regulatory authorities
  • Introduction of novel antiparasitic drugs by manufacturers
• Market Challenges
  • Adverse effects and risks associated with the drugs

Porter's Five Forces: A Strategic Tool for Navigating the Antiparasitic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antiparasitic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antiparasitic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antiparasitic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antiparasitic Drugs Market

A detailed market share analysis in the Antiparasitic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antiparasitic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antiparasitic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antiparasitic Drugs Market

A strategic analysis of the Antiparasitic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antiparasitic Drugs Market, highlighting leading vendors and their innovative profiles. These include Adva Care Pharma, Algen Healthcare Ltd., Amneal Pharmaceuticals LLC, Bayer AG, Ben Pharmaceuticals, Centurion Laboratories Private Limited, Cipla Ltd., Consern Pharma Limited, Dr.Reddys Laboratories Inc., F. Hoffmann-La Roche AG, Fredun Group, Garcia Life Sciences, Glaxosmithkline PLC, Healthy Life Pharma Private Limited, Ipca Laboratories, Jackson Laboratories Pvt Ltd., Mankind Pharma, Merck KgaA, Novartis AG, Sanofi, Soigner Pharma by Arlak Biotech, Sriwalls Health Care, Taj Life Sciences Pvt. Ltd., Weefsel Pharma, and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Antiparasitic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Anthelmintics, Antiprotozoals, Ectoparasiticides, and Endoparaciticides.
• Based on Form, market is studied across Injections, Oral Tablets/Capsules, and Topical Creams.
• Based on Indication, market is studied across Fleas, Intestinal Parasites, Lice, Malaria, Scabies, and Ticks.
• Based on Distribution Channel, market is studied across Offline and Online.
• Based on End-User, market is studied across Home Care Facilities, Hospitals & Clinics, and Veterinary Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing incidence and awareness of parasite infection across the globe
    • 5.1.1.2. Favorable government initiatives for parasite infection management
    • 5.1.1.3. Increasing investment in research and development activities
  • 5.1.2. Restraints
    • 5.1.2.1. Requirement of huge capital for drug development
  • 5.1.3. Opportunities
    • 5.1.3.1. Surge in approvals for antiparasitic drugs from several regulatory authorities
    • 5.1.3.2. Introduction of novel antiparasitic drugs by manufacturers
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects and risks associated with the drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antiparasitic Drugs Market, by Drug Type

• 6.1. Introduction
• 6.2. Anthelmintics
• 6.3. Antiprotozoals
• 6.4. Ectoparasiticides
• 6.5. Endoparaciticides

7. Antiparasitic Drugs Market, by Form

• 7.1. Introduction
• 7.2. Injections
• 7.3. Oral Tablets/Capsules
• 7.4. Topical Creams

8. Antiparasitic Drugs Market, by Indication

• 8.1. Introduction
• 8.2. Fleas
• 8.3. Intestinal Parasites
• 8.4. Lice
• 8.5. Malaria
• 8.6. Scabies
• 8.7. Ticks

9. Antiparasitic Drugs Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Offline
• 9.3. Online

10. Antiparasitic Drugs Market, by End-User

• 10.1. Introduction
• 10.2. Home Care Facilities
• 10.3. Hospitals & Clinics
• 10.4. Veterinary Clinics

11. Americas Antiparasitic Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Antiparasitic Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Antiparasitic Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Adva Care Pharma
• 2. Algen Healthcare Ltd.
• 3. Amneal Pharmaceuticals LLC
• 4. Bayer AG
• 5. Ben Pharmaceuticals
• 6. Centurion Laboratories Private Limited
• 7. Cipla Ltd.
• 8. Consern Pharma Limited
• 9. Dr.Reddys Laboratories Inc.
• 10. F. Hoffmann-La Roche AG
• 11. Fredun Group
• 12. Garcia Life Sciences
• 13. Glaxosmithkline PLC
• 14. Healthy Life Pharma Private Limited
• 15. Ipca Laboratories
• 16. Jackson Laboratories Pvt Ltd.
• 17. Mankind Pharma
• 18. Merck KgaA
• 19. Novartis AG
• 20. Sanofi
• 21. Soigner Pharma by Arlak Biotech
• 22. Sriwalls Health Care
• 23. Taj Life Sciences Pvt. Ltd.
• 24. Weefsel Pharma
• 25. Zydus Group